

# Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes

(Human Genome Project/DNA chip/gene discovery/T cell)

MARK SCHENA\*<sup>†</sup>, DARI SHALON<sup>‡</sup>, RENU HELLER\*, ANDREW CHAI\*, PATRICK O. BROWN<sup>§</sup>, AND RONALD W. DAVIS\*

\*Department of Biochemistry, Beckman Center, Stanford University Medical Center, Stanford, CA 94305; <sup>‡</sup>Synteni, Palo Alto, CA 94306; and <sup>§</sup>Department of Biochemistry and Howard Hughes Medical Institute, Beckman Center, Stanford University Medical Center, Stanford, CA 94305

Contributed by Ronald W. Davis, June 26, 1996

**ABSTRACT** Microarrays containing 1046 human cDNAs of unknown sequence were printed on glass with high-speed robotics. These 1.0-cm<sup>2</sup> DNA “chips” were used to quantitatively monitor differential expression of the cognate human genes using a highly sensitive two-color hybridization assay. Array elements that displayed differential expression patterns under given experimental conditions were characterized by sequencing. The identification of known and novel heat shock and phorbol ester-regulated genes in human T cells demonstrates the sensitivity of the assay. Parallel gene analysis with microarrays provides a rapid and efficient method for large-scale human gene discovery.

Biology has entered the genome era (1). Complete genome sequences for all of the model organisms and human will probably be available by the year 2003 (2). Torrents of human expressed sequence tags (ESTs) provide a starting point for elucidating the function of tens of thousands of cognate genes (3). Genome analysis will provide insights into growth, development, differentiation, homeostasis, aging, and the onset of diseases (1–3). A detailed understanding of the human genome will require the implementation of sophisticated methods for gene expression analysis and gene discovery.

Recently, a microarray-based method for high-throughput monitoring of plant gene expression was described (4). This “chip”-based approach involved using microarrays of cDNA clones as gene-specific hybridization targets to quantitatively measure expression of the corresponding plant genes (4, 5). A two-color fluorescence labeling and detection scheme facilitated sensitive differential expression analysis of different plant tissues (4, 5). The efficiency of this approach for studies in higher plants suggested the use of this method for human genome analysis (4–7). Here, we report the use of cDNA microarrays for human gene expression monitoring, biological investigation, and gene discovery.

## MATERIALS AND METHODS

**Human cDNA Clones.** The cDNA library was made with mRNA from human peripheral blood lymphocytes transformed with the Epstein–Barr virus. Inserts >600 bp were cloned into the lambda vector λYES-R to generate 10<sup>7</sup>–10<sup>8</sup> recombinants. Bacterial transformants were obtained by infecting *E. coli* strain JM107/λKC. Colonies were picked at random and propagated in a 96-well format, and minilysate DNA was prepared by alkaline lysis using REAL preps (Qiagen, Chatsworth, CA). Inserts were amplified by PCR in a 96-well format using primers (PAN132, 5'-CCTC-TATACTTTAACGTCAAGG; and PAN133, 5'-TTGTGTG-GAATTGTGAGCGG) complementary to the λYES polylinker and containing a six-carbon amino modification

(Glen Research, Sterling, VA) on the 5' end. PCR products were purified in a 96-well format using QIAquick columns (Qiagen).

**Microarray Preparation.** Amino-modified PCR products were suspended at a concentration of 0.5 mg/ml in 3× standard saline citrate (SSC) and arrayed from 96-well microtiter plates onto silylated microscope slides (CEL Associates, Houston) using high-speed robotics (4–7). A total of 1056 cDNAs, representing 1046 human clones and 10 *Arabidopsis* controls, were arrayed in 1.0-cm<sup>2</sup> areas. Printed arrays were incubated for 4 hr in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in H<sub>2</sub>O for 1 min, and once for 5 min in sodium borohydride solution (1.0 g of NaBH<sub>4</sub> dissolved in 300 ml of PBS and 100 ml of 100% ethanol). The arrays were submerged in H<sub>2</sub>O for 2 min at 95°C, transferred quickly into 0.2% SDS for 1 min, rinsed twice in H<sub>2</sub>O, air dried, and stored in the dark at 25°C.

**Fluorescent Probes.** Tissue mRNAs were purchased (CLONTECH). Jurkat mRNA was isolated as described by Schena *et al.* (4). Probes were made as described (4) with several modifications. The reverse transcriptase used here was Superscript II RNase H<sup>-</sup> (GIBCO). The Cy5-dCTP was purchased from Amersham. Each reverse transcription reaction contained 3.0 μg of total human mRNA. *Arabidopsis* control mRNAs were made by *in vitro* transcription of cloned HAT4, HAT22, and YesAt-23 cDNAs (4, 8, 9) using an RNA Transcription Kit (Stratagene). For quantitation, the mRNAs were doped into the reverse transcription reaction at ratios of 1:100,000, 1:10,000, and 1:1000 (wt/wt) respectively. Following the reverse transcription step, samples were treated with 2.5 μl of 1 M sodium hydroxide for 10 min at 37°C, then neutralized by adding 2.5 μl of 1 M Tris·HCl (pH 6.8) and 2.0 μl of 1 M HCl. Probe mixtures contained cDNA products derived from 3 μg of total mRNA, suspended in 5.0 μl of hybridization buffer (5× SSC plus 0.2% SDS).

**Hybridization and Scanning.** Probes were hybridized to 1.0-cm<sup>2</sup> microarrays under a 14 × 14 mm glass coverslip for 6–12 hr at 60°C in a custom-built hybridization chamber (4–7). Arrays were washed for 5 min at room temperature (25°C) in low stringency wash buffer (1× SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1× SSC/0.2% SDS). Arrays were scanned in 0.1× SSC using a fluorescence laser scanning device (4–7), fitted with a custom filter set (Chroma Technology, Brattleboro, VT). Accurate differential expression measurements (i.e., final fluorescence ratios) were obtained by taking the average of the ratios of two independent hybridizations.

Abbreviation: EST, expressed sequence tag.

Data deposition: The sequences reported in this paper have been deposited in the GenBank data base (accession nos. U56654–U56660). <sup>†</sup>To whom reprint requests should be addressed. e-mail: schena@cmgm.stanford.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

**Cell Culture.** Jurkat cells were grown in a tissue culture incubator (37°C and 5% CO<sub>2</sub>) in RPMI medium supplemented with 10% fetal bovine serum, 100 µg of streptomycin per ml, and 500 units of penicillin per ml. Heat shock corresponded to a 4-hr incubation at 43°C. Phorbol ester treated cells were grown for 4 hr in the presence of 50 ng of phorbol 12-myristate 13-acetate (PMA) per ml.

**RNA Blotting.** Dot blots were performed as described (4).

**DNA Sequencing.** Sequences were obtained using the PAN132 and PAN133 primers and a 373A automated sequencer, according to the instructions of the manufacturer (Applied Biosystems).

**Computer Graphics and Informatics.** Pseudocolor representations of fluorescent images were made with National Institutes of Health IMAGE software (version 1.52). Software for differential expression representations was purchased from Imaging Research (St. Catherine's, ON, Canada). Sequence searches were made to the nonredundant nucleotide data base at the National Center for Biotechnology Information (NCBI) using Macintosh BLAST software. The EST data base was accessed via the World Wide Web (<http://www.ncbi.nlm.nih.gov/>).

## RESULTS

**Gene Discovery and the Heat Shock Response.** Microarrays were used to examine the heat shock response in cultured human T (Jurkat) cells. Control (37°C) and heat-treated (43°C) cells were harvested and lysed, and total mRNA from the two cell samples was labeled by reverse transcriptase incorporation of fluorescein- and Cy5-dCTP, respectively. In a second set of labeling reactions, the fluorescent groups were "swapped" such that samples from control and heat-treated

samples were labeled with Cy5- and fluorescein-dCTP, respectively. Each pair of fluorescent probes was hybridized to a 1056-element microarray. The arrays were washed at a high stringency and scanned with a confocal laser scanning device to detect emission of the two fluorescent groups.

Hybridization signals were observed to >95% of the human cDNA array elements, but not to any of the *Arabidopsis* negative controls (Fig. 1). Fluorescence intensities spanned more than three orders of magnitude for the 1046 array elements surveyed (Fig. 1). Comparative expression analysis of heat shocked versus control cells in the two experiments revealed 17 array elements that displayed altered fluorescence ratios of  $\geq 2.0$ -fold (Figs. 1 and 2A). Of the 17 putative differentially expressed genes, 11 were induced by heat shock treatment and 6 displayed modest repression (Figs. 1 and 2A).

To determine the identity of the heat-regulated genes, cDNAs corresponding to each of the 17 array elements were sequenced on the proximal and distal end. Data base searches revealed perfect matches for 14 of the 17 clones, and in each case proximal and distal cDNA sequences mapped to the same gene (Table 1). Of the 1046 human genes examined on the microarray, the five most highly induced in heat-treated cells were heat shock protein 90 $\alpha$  (hsp90 $\alpha$ ), dnaJ, hsp90 $\beta$ , polyubiquitin, and t-complex polypeptide-1 (tcp-1) (Table 1). Three of the 17 clones did not match any entry in the public data base, though one of the clones (B7) exhibited significant homology to an EST from *Caenorhabditis elegans* (Table 1). Each of the novel sequences (B7-B9) exhibited  $\approx 2$ -fold induction (Table 1) and relatively low-level expression (Table 2).

To confirm the microarray results, mRNA levels for each of the genes were measured by RNA blotting. Each of the genes that displayed heat shock induction, including the three novel




FIG. 1. Human gene expression monitored on a microarray. Fluorescent scans represented in a pseudocolor scale correspond to expression levels. The array contains 10 *Arabidopsis* controls (upper left corner, elements 1–10) and 1046 human peripheral blood cDNAs. Fluorescent probes were prepared by labeling mRNA from Jurkat cells grown at 37°C (–Heat Shock, A) or 43°C (+Heat Shock, B). Array elements that display altered fluorescence intensity (white boxes) corresponded to genes activated (red boxes) or repressed (green boxes) by heat shock. The color bar was calibrated in separate experiments using known quantities (wt/wt) of *Arabidopsis* control mRNAs added to the labeling reaction. Microarray rows (at left) and columns (at the top) are demarcated at 10 element increments (white circles). (Bar = 1 mm.)




FIG. 2. Elemental displays of activated and repressed genes. Fluorescence ratios of two-color microarray scans (Fig. 1) are depicted schematically. Fluorescein-labeled probes from Jurkat cells subjected to (A) heat shock or (B) phorbol ester treatment were compared with Cy5-labeled probes from untreated cells. In a second set of reactions, the fluorescent groups were swapped (see text). The data represent the average of the ratios from two hybridizations, excluding values in which the difference of the two ratios was greater than half the average ratio. The color bar corresponds to expression ratios, which are independent of the absolute expression level of a given gene.

Table 1. Microarray elements corresponding to differentially expressed genes

| Clone | Row | Column | Ratio | Blast identity           | Accession no.  |
|-------|-----|--------|-------|--------------------------|----------------|
| B1    | 24  | 21     | 0.5   | CYC oxidase III          | J01415, J01415 |
| B2    | 1   | 31     | 0.5   | $\beta$ -Actin           | NR, X00351     |
| B3    | 15  | 8      | 0.5   | CYC oxidase III          | J01415, J01415 |
| B4    | 32  | 19     | 0.5   | CYC oxidase III          | J01415, J01415 |
| B5    | 17  | 8      | 0.5   | CYC oxidase III          | J01415, J01415 |
| B6    | 22  | 31     | 0.5   | $\beta$ -Actin           | NR, X00351     |
| B7*   | 5   | 4      | 2.0   | Novel†                   | U56653, U56654 |
| B8    | 2   | 19     | 2.0   | Novel†                   | U56655, U56656 |
| B9    | 14  | 5      | 2.2   | Novel†                   | U56657, U56658 |
| B10   | 7   | 8      | 2.4   | Polyubiquitin            | X04803, X04803 |
| B11   | 12  | 2      | 2.4   | TCP-1                    | X52882, X52882 |
| B12   | 28  | 2      | 2.5   | Polyubiquitin            | M17597, M17597 |
| B13   | 14  | 7      | 2.5   | Polyubiquitin            | X04803, X04803 |
| B14   | 20  | 9      | 2.6   | HSP90 $\beta$            | M16660, M16660 |
| B15   | 30  | 12     | 4.0   | DnaJ homolog             | D13388, D13388 |
| B16   | 10  | 5      | 5.8   | HSP90 $\alpha$           | X07270, X07270 |
| B17   | 13  | 16     | 6.3   | HSP90 $\alpha$           | M27024, X15183 |
| B18   | 7   | 19     | 2.0   | $\beta_2$ -microglobulin | S54761, M30683 |
| B19   | 21  | 30     | 2.1   | Novel†                   | U56659, U56660 |
| B20   | 3   | 26     | 2.2   | $\beta_2$ -microglobulin | S54761, M30683 |
| B21   | 1   | 18     | 2.6   | PGK                      | M11968, L00160 |
| B22   | 22  | 30     | 3.5   | NF- $\kappa$ B1          | Z47744, M55643 |
| B23   | 20  | 16     | 19    | PAC-1                    | L11329, L11329 |

Clone name, array position (Fig. 1), fluorescence ratio, sequence identity, and accession number of cDNAs that manifested a differential expression pattern with probes prepared from heat shock- (B1-17) or phorbol ester-treated (B18-23) Jurkat cells. Clones showing >98% identity over 300 nucleotides were assumed to be identical to known sequences. All genes are nuclear except CYC oxidase III (mitochondrial). Accession numbers reflect the highest score for proximal and distal sequence traces, respectively. CYC, cytochrome *c*; TCP-1, T-complex polypeptide; HSP, heat shock protein; PGK, phosphoglycerate kinase; NF- $\kappa$ B, nuclear factor-kappaB; PAC-1, phosphatase of activated cells; and NR, trace not readable due to the presence of poly(A)<sup>+</sup> tract.

\*B7 is 67% identical to an EST from *C. elegans* (D76026).

†No match in the public data bases.

Table 2. Human gene expression monitored by microarray and RNA blot analyses

| Clone | Blast identity           | Expression level, per 10 <sup>5</sup> mRNAs |       |          |       |
|-------|--------------------------|---|-------|----------|-------|
|       |                          | Microarray                                  | Ratio | RNA blot | Ratio |
| B1    | CYC oxidase III          | 92/46                                       | 0.5   | 100/80   | 0.8   |
| B2    | $\beta$ -Actin           | 240/120                                     | 0.5   | 270/280  | 1.0   |
| B3    | CYC oxidase III          | 36/18                                       | 0.5   | ND       | ND    |
| B4    | CYC oxidase III          | 76/38                                       | 0.5   | ND       | ND    |
| B5    | CYC oxidase III          | 62/31                                       | 0.5   | ND       | ND    |
| B6    | $\beta$ -Actin           | 180/89                                      | 0.5   | ND       | ND    |
| B7    | Novel (weakly to D76026) | 1.3/2.6                                     | 2.0   | 0.77/1.8 | 2.3   |
| B8    | Novel                    | 2.0/4.0                                     | 2.0   | 1.5/3.4  | 2.3   |
| B9    | Novel                    | 0.8/1.8                                     | 2.2   | 1.2/1.8  | 1.5   |
| B10   | Polyubiquitin            | 0.8/1.9                                     | 2.4   | 25/89    | 3.6   |
| B11   | TCP-1                    | 2.3/5.5                                     | 2.4   | 7.1/27   | 3.8   |
| B12   | Polyubiquitin            | 0.8/2.0                                     | 2.5   | ND       | ND    |
| B13   | Polyubiquitin            | 1.7/4.3                                     | 2.5   | ND       | ND    |
| B14   | HSP90 $\beta$            | 75/200                                      | 2.6   | 30/120   | 4.0   |
| B15   | DnaJ homolog             | 1.0/4.0                                     | 4.0   | 1.6/13   | 8.1   |
| B16   | HSP90 $\alpha$           | 0.6/3.5                                     | 5.8   | 3.2/29   | 9.1   |
| B17   | HSP90 $\alpha$           | 0.8/5.0                                     | 6.3   | 8.6/62   | 7.2   |
| B18   | $\beta_2$ -microglobulin | 1.0/2.0                                     | 2.0   | 5.4/15   | 2.8   |
| B19   | Novel                    | 1.2/2.5                                     | 2.1   | 4.5/9.5  | 2.5   |
| B20   | $\beta_2$ -microglobulin | 2.7/5.9                                     | 2.2   | ND       | ND    |
| B21   | Phosphoglycerate kinase  | 2.4/6.2                                     | 2.6   | 4.7/9.2  | 2.0   |
| B22   | NF-KB1                   | 1.7/6.0                                     | 3.5   | 0.65/4.7 | 7.2   |
| B23   | PAC-1                    | 0.5/9.5                                     | 19    | 0.21/15  | 71    |

Shown are expression levels per 100,000 mRNAs (wt/wt) of genes assayed with a microarray (Fig. 1) or RNA blot. Ratios correspond to values from cells subjected to heat shock (B1-17) or phorbol ester treatment (B18-23) relative to untreated cells. Clone and gene names are given in Table 1. ND, not determined.

sequences, exhibited elevated mRNA levels by dot blot analysis (Table 2). In all cases, expression ratios as determined by the two procedures differed by <2-fold for the genes identified in the heat shock experiments (Table 2). The two assays differed more widely in terms of assessing absolute expression levels; nonetheless, absolute expression as monitored on a microarray typically correlated with RNA blots to within a factor of five (Table 2).

**Phorbol Ester Signaling.** To explore a signaling pathway distinct from the heat shock response, microarrays were used to examine the cellular effects of phorbol ester treatment. Jurkat cells were treated with phorbol ester, harvested, lysed, and used as a source of mRNA. Samples of mRNA from untreated or phorbol ester-stimulated cells were labeled with reverse transcriptase. The probes were mixed, hybridized to microarrays, and scanned for fluorescence emission of the two fluorescent groups. A total of six array elements displayed  $\geq 2.0$ -fold elevated signals with probes from phorbol ester-treated cells relative to control samples (Fig. 2B).

To determine the identity of the phorbol ester-induced genes, clones corresponding to the six array elements were sequenced. Data base searches revealed perfect matches for five of the six sequences (Table 1). The two most highly induced genes were the *PAC-1* tyrosine phosphatase and nuclear factor-kappa B1 (*NF- $\kappa$ B1*); modest activation was observed for phosphoglycerate kinase and  $\beta_2$ -microglobulin (Table 1). One remaining clone (B19) did not match any entry in the public data base (Table 1). B19 displayed a 2.1-fold induction and, similar to the novel heat shock genes, a relatively low absolute expression level (Tables 1 and 2). All six of the phorbol ester-inducible genes displayed increased steady-state mRNA levels by RNA blotting (Table 2). *PAC-1* expression (Fig. 1; Table 2) defined a detection limit of  $\approx 1:500,000$  for the assay.

**Transcript Imaging in Human Tissues.** To determine whether microarrays could be used to monitor expression in human tissues, probes were prepared from human bone mar-

row, brain, prostate, and heart by labeling each mRNA sample with Cy5-dCTP. In a separate reaction, a control probe was prepared by labeling Jurkat mRNA with fluorescein-dCTP. The four Cy5-labeled probes were each mixed with an aliquot of the fluorescein-labeled control sample, and the four mixtures were hybridized to separate microarrays. The arrays were washed and scanned for fluorescence emission, and hybridization signals for each of the tissues samples were normalized to the Jurkat control to generate an expression profile for each of the 1046 clones present on the array.

Detectable expression was observed for all 15 of the heat shock and phorbol ester-regulated genes in the four tissue types examined (Fig. 3). In general, the expression level of each gene in Jurkat cells correlated rather closely with expression in the four tissues (Table 2; Fig. 3). Genes encoding  $\beta$ -actin and cytochrome *c* oxidase, the two most highly expressed of the 15 genes in Jurkat cells (Table 2), were highly expressed in bone marrow, brain, prostate, and heart (Fig. 3A). Expression of cytochrome *c* oxidase, hsp90 $\alpha$ , and the novel B7 sequence was significantly greater in heart than in the other tissues (Fig. 3).

## DISCUSSION

Many of the heat shock genes identified in this study encode factors that function either as molecular "chaperones" (HSP90 $\alpha$ , HSP90 $\beta$ , DnaJ, TCP-1) or as mediators of protein degradation (polyubiquitin). The identification of these sequences is consistent with the biochemical basis of heat shock induction (10–15). Proteins undergo denaturation at elevated temperatures, and those that fail to maintain proper conformation must be selectively degraded (10–15). It will be interesting to determine whether the three novel heat shock-inducible sequences (B7–B9) mediate protein folding and turnover or possess some other biochemical activity. Complete nucleotide sequence determination, conceptual translation, expression monitoring, and biochemical analysis should provide a detailed functional understanding of these genes.




FIG. 3. Transcript profiles of heat shock and phorbol ester-regulated genes. Gene expression levels per 100,000 mRNAs (*x*-axes) are shown for 15 genes (Table 1) in human bone marrow (red), brain (green), prostate (blue), and heart (yellow). Genes are grouped according to expression levels (A–C).

Phorbol ester, a potent activator of protein kinase C (16, 17), induced a set of genes distinct from those involved in the heat shock pathway. The most highly induced gene identified in this study, *PAC-1*, encodes a nuclear tyrosine kinase that may play a role in regulating transcription and cell cycle progression (18). NF-κB1, a second phorbol ester-inducible gene, is an intensively studied member of the Rel transcription factor family (19–21). The Rel proteins are activated by a large number of stimuli, including phorbol esters, cytokines, bacterial and viral pathogens, and ultraviolet light (19–21). Modest activation was observed for three sequences not known to be inducible by phorbol esters, including phosphoglycerate kinase, β<sub>2</sub>-microglobulin, and a novel human gene (B19). Extensive expression monitoring with microarrays should assist in understanding how each of these genes integrate into the highly complex phorbol ester signaling pathway.

It is striking that four novel human genes were discovered with an array of 1000 randomly chosen clones, particularly because the heat shock and phorbol ester signaling pathways have been so intensively studied (10–21). The facile discovery of these sequences underscores the fact that microarrays can be used for gene discovery in the absence of any sequence information. By this approach, clones are chosen at random from any library of interest and only those clones that display interesting expression patterns are sequenced and characterized. This parallel assay, coupled with a modest DNA sequencing facility, allows high-throughput human genome expression analysis and gene discovery.

Genes that are activated or repressed by a given stimulus provide functional clues to the cellular pathway involved (22–24). Detailed examination of these gene expression “signatures” can provide a dynamic view of the mode of action of a given signaling substance (22–24). Microarrays may thus allow rapid mechanistic examination of hormones, drugs, elicitors, and other small molecules; moreover, functional analysis of transcription factors, kinases, growth factors, cytokines, receptors, and other gene products should be possible. Efforts are underway to develop mRNA amplification strategies to enable probe preparation from minute tissue samples. This capability might allow for high-throughput patient screening in a clinical setting.

The current detection limit of the assay allows monitoring of transcripts that represent ≈1:500,000 (wt/wt) of the total mRNA. This 10-fold increase in sensitivity compared with the original report (4) was achieved largely by modifying the coupling chemistry, which reduced background fluorescence. The significance of this improvement is considerable in that approximately half the human genes identified in this study, including all four novel sequences, exhibited expression levels below the original detection limit of 1:50,000 (4).

The ability to detect 2-fold changes in expression was achieved by the use of two-color fluorescence in the labeling and detection schemes, digitized data collection, and custom software. The importance of this capability is underscored by the fact that nearly all of the genes examined here exhibited <6-fold changes in expression. The four novel genes, which showed ≤2.2-fold activation, were probably overlooked in previous screens that used conventional differential expression techniques. It may be possible to further improve the precision of the microarray assay by the use of closely related fluorescent analogs, such as Cy3 and Cy5, in the labeling and hybridization reactions.

Microarrays offer a number of advantages over other potential high-capacity approaches to expression analysis. The chip-based approach enables small hybridization volumes, high array densities, and the use of fluorescence labeling and detection schemes. These features provide a set of performance specifications that are unattainable with filter-based approaches (25, 26). The use of cDNA clones provides hybridization specificity that is not readily attained with oligo-

nucleotide arrays (27–30). The parallel format of the assay provides a simultaneous differential expression readout for >1000 genes. This contrasts with sequencing-based methods, which require serial data collection for expression analysis (31, 32). A commercial source of cDNA microarrays would greatly speed the use of a chip-based approach to expression analysis.

The availability of large numbers of ESTs (3) provides a rich resource of human cDNA clones for microarraying. The >400,000 ESTs in the public data bases represent a significant subset of all human genes (3, 33). Microarrays of thousands of ESTs will provide a powerful analytical tool for future human gene expression studies. The ≈100,000 genes in the human genome (2, 33) emphasize the need for microarrays of greater density. Attempts to improve microdeposition techniques are underway and should allow construction of arrays containing a complete set of human gene targets (<http://cmgm.stanford.edu/~schena/>). Microarrays of ≈100,000 cDNA elements would allow expression monitoring of the entire human genome in a single hybridization. This capacity, coupled with detailed biochemical analysis of the individual gene products, would greatly speed the functional analysis of the human genome.

We thank S. Elledge ([selledge@bcm.tmc.edu](mailto:selledge@bcm.tmc.edu)) for the human cDNA library, Qiagen representatives for help with plasmid purification, and A. J. Smith and colleagues at the Protein and Nucleic Acid (PAN) facility (Stanford) for oligonucleotide synthesis and DNA sequencing. We also thank members of the Davis, Brown, and Smith laboratories for critical comments and helpful discussions and Synteni employees for technical assistance. Support for R.W.D. was provided by the National Science Foundation (MCB9106011) and National Institutes of Health (R37HG00198) and for P.O.B. by the National Institutes of Health (3R21HG00450) and Howard Hughes Medical Institute. P.O.B. is an assistant investigator of the Howard Hughes Medical Institute.

1. Watson, J. D. (1993) *Gene* **135**, 309–315.
2. Collins, F. S. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 10821–10823.
3. Adams, M. D., Kelley, J. M., Gocayne, J. D., Dubnick, M., Polymeropoulos, M. H., Xiao, H., Merril, C. R., Wu, A., Olde, B., Moreno, R. F., Kerlavage, A. R., McCombie, W. R. & Venter, J. C. (1991) *Science* **252**, 1651–1656.
4. Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. (1995) *Science* **270**, 467–470.
5. Shalon, D. (1996) Ph.D. thesis (Stanford University).
6. Schena, M. (1996) *BioEssays* **18**, 427–431.
7. Shalon, D., Smith, S. J. & Brown, P. O. (1996) *Genome Res.* **6**, 639–645.
8. Schena, M. & Davis, R. W. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 8393–8397.
9. Schena, M. & Davis, R. W. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 3894–3898.
10. Jindal, S. (1996) *Trends Biotechnol.* **14**, 17–20.
11. Wilkinson, K. D. (1995) *Annu. Rev. Nutr.* **15**, 161–189.
12. Jakob, U. & Buchner, J. (1994) *Trends Biochem. Sci.* **19**, 205–211.
13. Becker, J. & Craig, E. A. (1994) *Eur. J. Biochem.* **219**, 11–23.
14. Cyr, D. M., Langer, T. & Douglas, M. G. (1994) *Trends Biochem. Sci.* **19**, 176–181.
15. Craig, E. A., Weissman, J. S. & Horwich, A. L. (1994) *Cell* **78**, 365–372.
16. Newton, A. C. (1995) *J. Biol. Chem.* **270**, 28495–28498.
17. Nishizuka, Y. (1995) *FASEB J.* **9**, 484–496.
18. Rohan, P. J., Davis, P., Moskaluk, C. A., Kearns, M., Krutzsch, H., Siebenlist, U. & Kelly, K. (1993) *Science* **259**, 1763–1766.
19. Thanos, D. & Maniatis, T. (1995) *Cell* **80**, 529–532.
20. Baeuerle, P. A. & Henkel, T. (1994) *Annu. Rev. Immunol.* **12**, 141–179.
21. Liou, H.-C. & Baltimore, D. (1993) *Curr. Opin. Cell Biol.* **5**, 477–487.
22. Cohen, G. B., Ren, R. & Baltimore, D. (1995) *Cell* **80**, 237–248.
23. Chan, A. C., Desai, D. M. & Weiss, A. (1994) *Annu. Rev. Immunol.* **12**, 555–592.
24. Crabtree, G. R. & Clipstone, N. A. (1994) *Annu. Rev. Biochem.* **63**, 1045–1083.
25. Gress, T. M., Hoheisel, J. D., Lennon, G. G., Zehetner, G. & Lehrach, H. (1992) *Mamm. Genome* **3**, 609–619.
26. Bernard, K., Auphan, N., Granjeaud, S., Victorero, G., Schmitt-Verhulst, A.-M., Jordan, B. R. & Nguyen, C. (1996) *Nucleic Acids Res.* **24**, 1435–1442.
27. Fodor, S. P. A., Read, J. L., Pirrung, M. C., Stryer, L., Lu, A. T. & Solas, D. (1991) *Science* **251**, 767–773.
28. Southern, E. M., Maskos, U. & Elder, J. K. (1992) *Genomics* **13**, 1008–1017.
29. Guo, Z., Guilfoyle, R. A., Thiel, A. J., Wang, R. & Smith, L. M. (1994) *Nucleic Acids Res.* **22**, 5456–5465.
30. Matson, R. S., Rampal, J., Pentoney, S. L., Jr., Anderson, P. D. & Coassin, P. (1995) *Anal. Biochem.* **224**, 110–116.
31. Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. (1995) *Science* **270**, 484–487.
32. Adams, M. D. (1996) *BioEssays* **18**, 261–262.
33. Fields, C., Adams, M. D., White, O. & Venter, J. C. (1994) *Nat. Genet.* **7**, 345–346.